Main Article Content
type 2 diabetes mellitus; insulin resistance; adipocyte fatty acid-binding protein; serum uric acid; correlation
Aim: To explore the correlations of insulin function with the levels of adipocyte fatty acid-binding protein (A-FABP) and serum uric acid (SUA) in patients with newly diagnosed type 2 diabetes mellitus (T2DM) with abdominal obesity. Methods: A total of 218 newly diagnosed T2DM patients were divided into abdominal obesity (n=98) and non-abdominal obesity groups (n=120) according to waist circumference. Their baseline clinical data, laboratory indices, A-FABP and SUA levels, homeostasis model assessment of insulin resistance (HOMA-IR) and HOMA-β were compared. The correlations of HOMA-IR with A-FABP, SUA levels and HOMA-β were subjected to Pearson’s analysis. The risk factors for IR were explored by logistic regression analysis. Results: The abdominal obesity group had significantly higher body mass index (BMI), waist circumference, waist-to-hip ratio, diastolic blood pressure and systolic blood pressure than those of non-abdominal obesity group (P<0.05). Compared with non-abdominal obesity group, the abdominal obesity group had higher levels of very low-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglyceride (TG), total cholesterol, aspartate aminotransferase, alanine aminotransferase and fasting serum insulin (P<0.05), and lower high-density lipoprotein-cholesterol level (P<0.05). The abdominal obesity group had higher HOMA-IR, HOMA-β and A-FABP, SUA levels than those of non-abdominal obesity group (P<0.05). HOMA-IR was positively correlated with A-FABP, SUA levels and HOMA-β (P<0.0001). BMI, waist circumference, as well as TG, A-FABP and SUA levels were risk factors for IR (P<0.05). Conclusion: In newly diagnosed T2DM patients with abdominal obesity, A-FABP and SUA levels significantly rise, being positively correlated with IR. Therefore, reducing lipids and weight together with controlling A-FABP and SUA levels may be important strategies for relieving IR and preventing T2DM complicated with abdominal obesity.
2. Tangvarasittichai S, Pongthaisong S, Tangvarasittichai O. Tumor Necrosis Factor-Α, Interleukin-6, C-Reactive Protein Levels and Insulin Resistance Associated with Type 2 Diabetes in Abdominal Obesity Women. Indian J Clin Biochem 2016; 31: 68-74.
3. Gómez-Marcos MÁ, Recio-Rodríguez JI, Patino-Alonso MC, et al. Evolution of target organ damage and haemodynamic parameters over 4 years in patients with increased insulin resistance: the LOD-DIABETES prospective observational study. BMJ Open 2016; 6: e010400.
4. Mudumbi JBN, Ntwampe SKO, Mekuto L, Matsha T, Itoba-Tombo EF. The role of pollutants in Type 2 Diabetes Mellitus (T2DM) and their prospective impact on phytomedicinal treatment strategies. Environ Monit Assess 2018; 190: 262.
5. Ha KN, Xia Y, Tran Y, et al. Investigating the Conformational Transitions of Human Adipocyte Fatty Acid Binding Protein Upon Binding Leukotriene B4 by Solution-State NMR Spectroscopy. Biophys J 2018; 114: 26a.
6. Bauer F, Pagonas N, Seibert FS, et al. Serum Uric Acid and Arterial Function After Renal Transplantation. Ann Transplant 2017; 22: 431-9.
7. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva: World health organization, 1999.
8. Joint committee for guideline revision. 2016 Chinese Guideline for the Management of Dyslipidemia in Adults. J Geriatr Cardiol 2018; 15: 1-29.
9. Fang F, Zhan YF, Zhuo YY, Yin DZ, Li KA, Wang YF. Brain atrophy in middle-aged subjects with Type 2 diabetes mellitus, with and without microvascular complications. J Diabetes 2018; 10: 625-32.
10. Scott EM, Carpenter JS, Iorfino F, et al. What is the prevalence, and what are the clinical correlates, of insulin resistance in young people presenting for mental health care? A cross-sectional study. BMJ Open 2019; 9: e025674.
11. Zeng H, Luo M, Li Z, et al. Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis. BMJ Open 2019; 9: e029426.
12. Khan A, Faheem M, Shah ST, et al. Frequency of abdominal obesity and its association with diabetes mellitus among people of Peshawar. J Ayub Med Coll Abbottabad 2015; 27: 617-9.
13. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015; 125: 1790-2.
14. Hikasa S, Shimabukuro S, Hideta K, et al. Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study. J Pharm Health Care Sci 2019; 5: 12.
15. Lambert EA, Hachem M, Hemmes R, et al. Serum uric acid and the relationship with subclinical organ damage in adults. J Hypertens 2017; 35: 745-52.
16. Li JC, Wu DA, Hou JS, Subeq YM, Chen HD, Hsu BG. High Serum Adipocyte Fatty Acid Binding Protein Is Associated with Metabolic Syndrome in Patients with Type 2 Diabetes. J Diabetes Res 2016; 2016: 8380279.
17. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013; 62: 3307-15.
18. Qiu QY, Zhang BL, Zhang MZ, et al. Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of Inner Mongolians in China. Biomed Environ Sci 2018; 31: 300-5.